申请人:The General Hospital Corporation
公开号:US10408820B2
公开(公告)日:2019-09-10
The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
该申请描述了一种用于鉴定整合素 CD11b/CD18 小分子调节剂和能够调节该受体活性的小分子的检测方法。在某些实施方案中,此类化合物可用于治疗选自炎症、免疫相关疾病、癌症、缺血再灌注损伤、中风、与血管损伤相关的新内膜增厚、牛皮癣、新生儿阻塞性肾病和心血管疾病的疾病或病症、或在其他实施方案中,用于治疗选自免疫缺陷、获得性免疫缺陷综合征(艾滋病)、髓过氧化物酶缺乏、Wiskott-Aldrich 综合征、慢性肉芽肿病、高 IgM 综合征、白细胞粘附缺陷、Chediak-Higashi 综合征和严重联合免疫缺陷的疾病或病症。